Every oncology pitch deck this spring leads with first-in-class. The money says otherwise. Of the ten largest unapproved oncology opportunities forecast through 2032, only two qualify as genuinely first-in-class, and both are just direct shots at mutant KRAS.
7 min read
Oncology
Therapeutic Thursday: The Deals Are Outrunning the Data in Oncology's Next Wave
Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?
